Geoffrey R. Oxnard

Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types

Selpercatinib in <i>RET</i> Fusion–Positive Non–Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial

Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation

Putting comprehensive genomic profiling of ctDNA to work: 10 proposed use cases

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

Germline <i>EGFR</i> Mutations and Familial Lung Cancer

Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types

Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <i>EGFR</i> -Mutant and <i>RET</i> Fusion-Positive Lung Cancers

Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma

Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer

Tumor Fraction Correlates With Detection of Actionable Variants Across &gt; 23,000 Circulating Tumor DNA Samples

Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer

Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)

Implementation Challenges and Disparities in Molecular Testing for Patients With Stage IV NSCLC: Perspectives from an Urban Safety-Net Hospital

Intracranial Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

Comparative Genomic Analysis of Intrahepatic Cholangiocarcinoma: Biopsy Type, Ancestry, and Testing Patterns

Integration of Immunotherapy into Adjuvant Therapy for Resected Non-Small-Cell Lung Cancer: ALCHEMIST Chemo-Io (ACCIO)

FP14.07 Combination Osimertinib plus Selpercatinib for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) with Acquired RET fusions

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC

Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib

ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.

Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer

PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers